Estrella Immunopharma, Inc.

ESLA · NASDAQ
Analyze with AI
12/31/2024
6/30/2024
12/31/2022
6/30/2022
Operating Activities
Net Income-$8,848-$7,312-$996-$1,685
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$29$0
Stock-Based Comp.$0$1,195$0$130
Change in WC$776-$9,951$577$113
Other Non-Cash$509$0-$654-$1
Operating Cash Flow-$7,640-$16,068-$1,044-$1,442
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0-$45,186
Inv. Sales/Matur.$0$0$36,170$0
Other Inv. Act.$0$4,961$0$0
Investing Cash Flow$0$4,961$36,170-$45,186
Financing Activities
Debt Repay.-$10,000$0$499$0
Stock Issued$79$0$0$46,892
Stock Repurch.-$569-$354-$36,113-$25
Dividends Paid$0$0$0$0
Other Fin. Act.$9,579$13,148$50$5,530
Financing Cash Flow-$489$12,794-$35,564$5,530
Forex Effect$0$0$0$45,186
Net Chg. in Cash-$8,129$1,686-$438$4,088
Supplemental Information
Beg. Cash$9,046$2,479$479$0
End Cash$917$4,165$41$4,088
Free Cash Flow-$7,640-$16,068-$1,044-$1,442
Estrella Immunopharma, Inc. (ESLA) Financial Statements & Key Stats | AlphaPilot